TITLE

Clinic Roundup

PUB. DATE
May 2011
SOURCE
BioWorld Today;5/24/2011, Vol. 22 Issue 100, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on several issues involving clinical trials. Anavex Life Sciences Corp. announced that the safety review committee for the Phase I trial of ANAVEX 2-73 approved skipping the dosage received by the volunteers to the 10 milligram (mg) dose cohort. Celladon Corp. reported continued improvements in clinical outcomes in advanced heart failure patients treated with Mydicar. Oxford BioMedica Plc reported that the Phase I/II trial of gene therapy candidate ProSavin continued to show a favorable safety profile.
ACCESSION #
60915225

 

Related Articles

  • Oxford BioMedica Gearing Up For Phase I/II ProSavin Study. Moran, Nuala // BioWorld International;12/19/2007, Vol. 12 Issue 51, p2 

    This article reports that Oxford BioMedica PLC received approval to start a Phase I/II trial of its ProSavin treatment for Parkinson's disease in England. The approval made it the first gene therapy for that condition to be tested in Europe, and the first use in humans of the company's...

  • Oxford BioMedica to Extend Parkinson's Therapy Trial. Moran, Nuala // BioWorld International;12/29/2010, Vol. 15 Issue 51, p1 

    The article announces the expansion of the ProSavin gene therapy trial of Oxford BioMedica PLC. The ProSavin trial in Parkinson's disease will extend to a second center and increase the dose to that which showed the greatest efficacy in animal models. In the trial, ProSavin proved to be safe and...

  • First Parkinson's Gene Therapy Planned by Oxford Biomedica. Moran, Nuala // BioWorld International;3/12/2008, Vol. 13 Issue 11, p1 

    The article reports on the first European trial of a gene therapy to treat Parkinson's disease which will be conducted by Oxford Biomedica PLC. The neurosurgery required to administer the trial has been booked, but the company has agreed with the Henri Mondor Hospital in Paris, France, where the...

  • First part of MetXia trial a success.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p4 

    Reports on the success of the BC1 clinical trial for the anti-cancer product MetXia by Oxford BioMedica.

  • Oxford BioMedica Reports Gene Therapy Trial Progress. Moran, Nuala // BioWorld International;6/16/2010, Vol. 15 Issue 24, p1 

    This article reports on the positive results obtained by Oxford BioMedica PLC from its two-year ProSavin gene therapy trial in Parkinson's disease amid continued negotiations with potential partners. Results of the study showed that patients in the higher dose group experienced an overall...

  • Clinic Roundup.  // BioWorld Today;10/15/2010, Vol. 21 Issue 200, p2 

    This section offers news briefs on clinical trials, including results from Infinity Pharmaceuticals Inc.'s Phase II study of IPI-504 intravenous heat-shock protein 90 chaperone inhibitor and Phase III results Oxford BioMedica plc's TroVax Renal Immunotherapy Survival Trial.

  • Oxford BioMedica Presses Hard to Partner TroVax. Moran, Nuala // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the increased efforts of Oxford BioMedica PLC in its quest of finding a partner for its TroVax gene therapy. The move came after the product received clearance form the U.S. Food and Drug Administration (FDA) on its further development in multiple cancers. The review...

  • Oxford's $31.5M is Bargaining Chip to Push ProSavin Forward. Moran, Nuala // BioWorld International;12/15/2010, Vol. 15 Issue 49, p2 

    The article reports on the fund raised by Oxford BioMedica plc in a rights issue to improve its balance sheet and negotiating position as it works with the ProSavin Parkinson's disease gene therapy. The company will spend 5.4 million British pounds for its LentiVector viral gene delivery...

  • Oxford BioMedica Using Sanofi Deal As Catalyst For Growth. Moran, Nuala // BioWorld International;9/19/2007, Vol. 12 Issue 38, p1 

    The article reports that Oxford Biomedica plc is revamping its business strategy. The move follows the deal with Sanofi-Aventis SA involving the cancer gene therapy product Trovax. Oxford Biomedica CEO Alan Kingsman said that they plan to become a fully-integrated biotechnology company. Details...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics